GIAPREZA™ (angiotensin II) increases blood pressure in adults with septic or other distributive shock.
The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in the randomized, double-blind, placebo-controlled ATHOS-3 study. There was a higher incidence of venous and arterial thromboembolic events in patients who received GIAPREZA compared to placebo treated patients in the Phase 3 study [13% (21/163 patients) vs. 5% (8/158 patients)]. The major imbalance was in venous thrombosis. Use concurrent venous thromboembolism prophylaxis.
The most common adverse reactions reported in greater than 10% in GIAPREZA-treated patients were thromboembolic events. Adverse reactions occurring in ≥4% of patients treated with GIAPREZA and ≥1.5% more often than placebo-treated patients in the ATHOS-3 study were thromboembolic events (including deep vein thrombosis), thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.
Angiotensin converting enzyme inhibitors may increase response to GIAPREZA.
Angiotensin II receptor blockers may reduce response to GIAPREZA.
Reference: 1. GIAPREZA™ (angiotensin II) [package insert]. San Diego, CA: La Jolla Pharmaceutical Company; 2017.
GIAPREZA™ is a trademark of La Jolla Pharmaceutical Company.
© 2018 La Jolla Pharmaceutical Company
This site is intended for a healthcare professional audience.